Higher-order aberrations were corrected by around 75% in eyes with keratoconus fitted with Zenlens Chroma HOA, according to data presented at the Global Specialty Lens Symposium. “Patients with keratoconus absolutely gain the most [from higher-order aberration-correcting lenses], and that has everything to do with the back surface of their cornea,” Jason Jedlicka, OD, FAAO, FSLS, clinical professor and chief of cornea and contact lens service at Indiana University School of Optometry, told Healio. “It’s the posterior cornea that creates the [higher-order aberrations]

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04323-5Infographic: effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the centre of the macula and good visual acuity (DRCR Protocol V Study)

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04246-1Infographic: study design of the QUASAR randomised trial of aflibercept 8 mg in retinal vein occlusion

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04312-8Peripheral vascular scorching with posterior pole ember glow—hyperacute outer retinal dysfunction

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04315-5Vitreous seeding in metastatic cutaneous melanoma

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04299-2Focal scleral nodule presenting as a depigmented lesion

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04309-3Dropless cataract surgery: comparing sub-Tenon’s and topical steroids for postoperative inflammation prophylaxis

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04331-5Differentiation of macular atrophy secondary to neovascular age-related macular degeneration vs. de novo geographic atrophy: a multimodal analysis

Eye, Published online: 19 February 2026; doi:10.1038/s41433-026-04303-9Correlation between blood glucose levels and endophthalmitis risk after intravitreal injections of anti-vascular endothelial growth factor

WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Murtaza K. Adam, MD, of Colorado Retina Associates, discusses real-world data coming in 2026. He said he is excited about data on Eylea HD (aflibercept 8 mg, Regeneron). Adam said there is already “robust” real-world data on Vabysmo (faricimab-svoa, Genentech) in neovascular age-related macular degeneration and diabetic macular edema, and “we are looking forward to seeing how the second-generation molecules altogether fare and compare to one another.”

Mission Statement: To be the indispensable source of ophthalmic knowledge by promptly publishing innovative, clinically relevant research through consistent and authoritative peer review and, thereby, to be the first choice of authors for their important manuscripts.

A 66-year-old man had nebulomacular corneal opacities, iris atrophy, and corectopia along with coarse facial skin, resorbed digits, anesthetic patches, and healed trophic skin ulcers. What would you do next?

This case report discusses a diagnosis of B-cell lymphoma mucosa-associated lymphoid tissue (MALT) in the conjunctiva of a young boy who presented with a painless, enlarging conjunctival mass.

This cohort study assesses patterns in medical school students who matched with ophthalmology residency programs from 2021 to 2023, according to candidates’ sex, race, and ethnicity.

This cohort study using data from the Sight Outcomes Research Collaborative (SOURCE) data repository assesses how intraocular pressure levels influence the decision to initiate or escalate glaucoma therapy in clinical practice.

This secondary analysis of the Mega Donna Mega (MDM) randomized clinical trial investigated if early longitudinal changes in proteomic profiles in extremely preterm infants are associated with the development of severe retinopathy of prematurity.

This case report describes a case of Peters anomaly with central corneal neovascularization diagnosed in a female toddler who presented with acute intracorneal hemorrhage in the right eye.

Retinopathy of prematurity (ROP) remains one of the leading causes of preventable childhood blindness, arising at the intersection of neonatal survival gains and uneven health system capacity to safeguard visual outcomes. In this issue of JAMA Ophthalmology, Wong and colleagues present a timely global analysis using data from the Global Burden of Disease 2021 study, integrating socioeconomic and health care indicators with machine-learning models to forecast ROP-related visual impairment through 2050. Their findings reveal an apparent paradox: while the global burden of ROP-related blindness has declined, prevalence is rising in middle- and upper-middle-income regions. Rather than indicating regression, this pattern reflects a turning point in the global evolution of neonatal care—when advances in neonatal survival outpace the development of screening, follow-up, and rehabilitation systems. Viewing these shifts through a health-system lens provides crucial insight into how global progress can be sustained without deepening inequities.

This case report discusses how long-read sequencing enables phasing and complements clinical testing to provide a complete genetic diagnosis in TYR-associated oculocutaneous albinism.

This cross-sectional study examines global trends in retinopathy of prematurity−related visual impairment and identifies risk factors for increased prevalence of visual loss.

A retrospective study found that stopping topical corticosteroid eyedrops within the first few years after Descemet membrane endothelial keratoplasty (DMEK) could increase the risk of graft rejection.

NIH Director Jay Bhattacharya, MD, PhD, has been picked to also serve as acting director of the CDC, a White House official confirmed to Healio. Bhattacharya will oversee both agencies until a permanent CDC director is nominated and confirmed, the official said. Jim O’Neill, who served as acting CDC director for 5-plus months until last Friday, will be nominated to be the next head of the National Science Foundation, according to the official. “Both are eminently qualified for these positions, and the White House has confidence in them to deliver on the President’s agenda,” the official told

Overview of the design, clinical performance, and key considerations of the two FDA-approved intracameral implants

NIH Director Jay Bhattacharya, MD, PhD, has been picked to also serve as acting director of the CDC, a White House official confirmed to Healio. Bhattacharya will oversee both agencies until a permanent CDC director is nominated and confirmed, the official said. Jim O’Neill, who served as acting CDC director for 5-plus months until last Friday, will be nominated to be the next head of the National Science Foundation, according to the official. “Both are eminently qualified for these positions, and the White House has confidence in them to deliver on the President’s agenda,” the official told

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA approved an expanded age indication for the EVO/EVO+ Visian Implantable Collamer Lens in the U.S. Previously approved for patients between the ages of 21 to 45 years, the EVO ICL is now available for use in patients between the ages of 21 to 60 years, according to a press release from STAAR Surgical. The EVO ICL is indicated in phakic eyes to correct/reduce myopia in those with spherical equivalent ranging from –3 D to –20 D at the spectacle plane, myopic astigmatism correction in those with spherical